Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
G. Romano, F. Paradiso, P. Li, P. Shukla, L. N. Barger, O. El Naggar, J. P. Miller, R. J. Liang, T. L. Helms, A. J. Lazar, J. A. Wargo, F. Taraballi, J. C. Costello, L. N. Kwong
The paper shows that delivering Cxcl9 via microparticles enhances the effectiveness of BRAF inhibitors in melanoma by reducing minimal residual disease relapse.
bioRxiv · May 24, 2022Cancer Biology